The loss of cholinergic neurons and reduced choline acetyltransferase in Alzheimer’s disease (Francis et al., 1999) lies behind the widespread use of cholinesterase inhibitors to enhance cholinergic transmission and thereby alleviate cognitive symptoms in Alzheimer’s disease (Rogers et al., 1998). This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.